On 20 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...
U.S. pharmaceutical company Eli Lilly is expected to unveil the top-line results (key findings from phase 3 clinical trials) of its new drug component ‘Lemternectuk’, being developed as a successor to ...
On 18 March, Eisai presented four-year data from its OLE period of its Phase III CLARITY-AD trial of Leqembi to treat early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results